Straits Times Index
3,296.43 -8.56 (-0.26%) Nikkei
38,789.10 -131.16 (-0.34%) Hang Seng
19,433.14 +56.61 (+0.29%) FTSE 100
8,438.65 -7.15 (-0.08%) Bitcoin USD
65,481.09 -363.40 (-0.55%) CMC Crypto 200
1,377.67 -16.38 (-1.17%)
Cartesian Therapeutics, Inc. (RNAC)
After hours:
| Previous close | 26.65 |
| Open | 26.84 |
| Bid | 25.84 x 100 |
| Ask | 26.47 x 200 |
| Day's range | 25.49 - 26.84 |
| 52-week range | 11.66 - 42.60 |
| Volume | |
| Avg. volume | 69,431 |
| Market cap | 468.749M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET. A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at www.ca
- GlobeNewswire
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Topline data from Phase 2b trial of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024 On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoimmune indications in 2H24 New headquarters expected to support scale of wholly owned, in-house cGMP manufacturing capabilities for clinical and commercial supply of Company’s pipeline of mRNA cell therapy produ
- Business Wire
Cartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., May 06, 2024--Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On May 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company’s common stock with an exercise price of $22.64, the closing trading price of the Company’s common stock on the Nas
